Alumis Inc.

Alumis Inc. is a clinical-stage biopharmaceutical company headquartered in South San Francisco, California, focused on transforming treatment for immune-mediated diseases. According to its official website, the company is "advancing a late-stage portfolio of next-generation targeted therapies to optimize patient outcomes across a wide range of immune-mediated diseases." Its stated mission is to "Transform Therapies, Reimagine Lives" by empowering people affected by immune-mediated conditions to reimagine their lives. The company's scientific approach centers on precision drug development powered by a proprietary data analytics platform. Alumis builds on integrated scientific insights to drive smarter therapeutic development, aiming to offer patients more targeted and convenient treatment options without the downsides of injections and broad immunosuppression. Its pipeline is led by oral tyrosine kinase 2 (TYK2) inhibitors, including envudeucitinib and A-005, designed to block TYK2 and its associated cytokine pathways—an approach widely validated as effective, safe, and well-tolerated for immune-mediated diseases. Alumis has identified approximately 20 diseases impacted by TYK2 through extensive genomic analysis, including psoriasis, lupus (SLE), psoriatic arthritis, rheumatoid arthritis, Crohn's disease, and ulcerative colitis. The company also sees a genetic rationale for TYK2 inhibition in neuroinflammatory diseases such as Parkinson's disease. In addition to its TYK2 portfolio, Alumis is developing lonigutamab, a potent anti–insulin-like growth factor 1 receptor (anti-IGF-1R) monoclonal antibody with a novel mechanism of action for thyroid eye disease (TED), providing a convenient subcutaneous route of administration. The company has stated it is exploring strategic options for the lonigutamab program. Alumis is led by President, Chief Executive Officer, and Chairman of the Board Martin Babler, who previously served as President and CEO of Principia Biopharma until its acquisition by Sanofi in October 2020, and held leadership roles at Talima Therapeutics, Genentech, and Eli Lilly. The leadership team also includes executives responsible for development, technical operations, commercial, medical, scientific, quality and regulatory, business and strategy, immunology and translational science, legal, and finance functions. As a clinical-stage company, Alumis reports financial results quarterly and participates in investor conferences. Recent news highlighted on its website includes topline results from the envudeucitinib Phase 2b trial in systemic lupus erythematosus (SLE) announced September 1, 2026, and second quarter 2026 financial results reported August 13, 2026. The company is based in South San Francisco, United States.

Alumis Inc. is a clinical-stage biopharmaceutical company based in South San Francisco, California, focused on developing therapies for immune-mediated diseases. The company describes its mission as transforming treatment for immune-mediated diseases and empowering people to reimagine their lives. Its approach combines a late-stage portfolio of next-generation targeted therapies with a precision development strategy powered by a proprietary data analytics platform. The company's pipeline is anchored in oral tyrosine kinase 2 (TYK2) inhibition. TYK2 is a naturally occurring enzyme that mediates immune signaling pathways in both innate and adaptive immunity and plays a key role in inflammatory cascades that can become dysregulated in disease. Alumis's oral TYK2 inhibitor pipeline features envudeucitinib and A-005, designed to offer patients more targeted, convenient options without the downsides of injections and broad immunosuppression. Through extensive genomic analysis, Alumis has identified approximately 20 diseases impacted by TYK2, including psoriasis, lupus (SLE), psoriatic arthritis, rheumatoid arthritis, Crohn's disease, and ulcerative colitis. The company's data analytics also support a genetic rationale for TYK2 inhibition in neuroinflammatory diseases such as Parkinson's disease. Genetic studies cited by the company show that 3–5% of the population naturally carry a TYK2 variant where its function is inhibited, which is shown to be protective against immune-mediated diseases without an increase in opportunistic infections, malignancies, or cardiovascular signals. Beyond TYK2, Alumis is developing lonigutamab, a potent anti–insulin-like growth factor 1 receptor (anti-IGF-1R) monoclonal antibody with a novel mechanism of action for thyroid eye disease (TED). IGF-1R is a transmembrane receptor tyrosine kinase that regulates cell growth, proliferation, differentiation, and survival, and it forms a functional receptor complex with thyroid-stimulating hormone receptor (TSHR) on the surface of orbital fibroblasts behind the eye. Lonigutamab is designed to provide a convenient subcutaneous route of administration and potential safety benefits while retaining the clinically validated efficacy of anti-IGF-1R therapy. The company has stated it is currently exploring strategic options for the lonigutamab program. Alumis is led by President, Chief Executive Officer, and Chairman of the Board Martin Babler. Prior to Alumis, Babler served as President and CEO of Principia Biopharma until its acquisition by Sanofi in October 2020. Before Principia, he was President and CEO of Talima Therapeutics from 2007 to 2011, and from 1998 to 2007 he held several positions at Genentech, most notably as Vice President, Immunology Sales and Marketing. He also previously served at Eli Lilly and Company in positions focused on sales, sales management, global marketing, and business development. Babler serves on the boards of Prelude Therapeutics Inc., MapLight Therapeutics Inc., and the Biotechnology Innovation Organization. The broader leadership team includes executives covering development, technical operations, commercial, medical, scientific, quality and regulatory, business and strategy, immunology and translational science, legal, and finance. As a clinical-stage company, Alumis reports financial results quarterly and engages with investors through conferences. Recent milestones highlighted on its website include topline results from the envudeucitinib Phase 2b trial in systemic lupus erythematosus (SLE) announced September 1, 2026, and second quarter 2026 financial results reported August 13, 2026.

• Alumis reports second quarter 2026 financial results and highlights recent achievements.

• Alumis announces topline results from the envudeucitinib Phase 2b trial in systemic lupus erythematosus (SLE).

• Alumis announces participation in upcoming September investor conferences.

A clinical-stage biopharmaceutical company advancing a late-stage portfolio of next-generation targeted therapies for immune-mediated diseases, with a precision approach powered by proprietary data analytics.

• Envudeucitinib

  An oral tyrosine kinase 2 (TYK2) inhibitor in late-stage development for immune-mediated diseases, including systemic lupus erythematosus (SLE).

• A-005

  An oral TYK2 inhibitor in the company's pipeline for immune-mediated diseases.

• Lonigutamab

  A potent anti–insulin-like growth factor 1 receptor (anti-IGF-1R) monoclonal antibody with a novel mechanism of action for thyroid eye disease (TED), administered subcutaneously. Alumis is exploring strategic options for this program.

1. 1Alumis Inc. official website homepagealumis.com
2. 2Alumis Inc. leadership team and Board of Directorsalumis.com
3. 3About TYK2 | Alumis Inc.alumis.com
4. 4About IGF-1R | Lonigutamab | Alumis Inc.alumis.com
5. 5Alumis Inc. (United States) - Wikidatawikidata.org